{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:21:53Z","timestamp":1789788113877,"version":"4.0.1"},"reference-count":20,"publisher":"Bioscientifica","issue":"1","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Immune checkpoint inhibitors have shown promising results in different cancers, and correlation between immune infiltration, expression of programmed death-ligand 1 (PD-L1) by tumor cells and response to immunotherapy has been reported. There is limited knowledge regarding the immune microenvironment of small bowel (SB) neuroendocrine tumors (NETs). This work was aimed at characterizing the immune landscape of SB NETs. Expression of PD-L1 and programmed death-1 (PD-1) was evaluated by immunohistochemistry in 102 surgically resected, primary NETs of the duodenum, jejunum and ileum. Extent and characteristics of the tumor-associated immune infiltrate were also assessed and investigated in their prognostic potential. We detected the expression of PD-L1 in \u22651 and \u226550% of tumor cells in 40\/102 (39%; 95% CI, 30\u201349%) and 14\/102 (14%; 95% CI, 8\u201322%) cases respectively. Intratumor host immune response was apparently absent in 35\/102 cases (34%; 95% CI, 25\u201344%), mild to moderate in 46\/102 samples (45%, 95% CI, 35\u201355%), intense in 21\/102 tumors (21%, 95% CI, 13\u201330%). Expression of PD-L1 and extent of immune infiltration were significantly higher in duodenal NETs as compared with jejunal\/ileal NETs. A marked peritumoral host response was organized as ectopic lymph node-like structures in 18\/102 cases (18%; 95% CI, 11\u201326%). Neither PD-L1 expression nor the degree of immune infiltration showed any prognostic significance. Overall, the immune landscape of SB NETs is heterogeneous, with adaptive immune resistance mechanisms prevailing in duodenal NETs. Clinical trials of immune checkpoint inhibitors should take into account the immune heterogeneity of SB NETs.<\/jats:p>","DOI":"10.1530\/erc-18-0189","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T07:11:41Z","timestamp":1536045101000},"page":"119-130","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":47,"title":["Analysis of the immune landscape of small bowel neuroendocrine tumors"],"prefix":"10.1530","volume":"26","author":[{"given":"M","family":"Cives","sequence":"first","affiliation":[{"name":"Department of GI Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Strosberg","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Al Diffalha","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Coppola","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref41","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/MPA.0000000000001150","article-title":"Characterization of the neuroendocrine tumor immune microenvironment","volume":"47","year":"2018","journal-title":"Pancreas"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","year":"2007","journal-title":"Virchows Archiv"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/ng.2821","article-title":"Somatic mutation of CDKN1B in small intestine neuroendocrine tumors","volume":"45","year":"2013","journal-title":"Nature Genetics"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","year":"2017","journal-title":"JAMA Oncology"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00262-007-0382-4","article-title":"CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients","volume":"57","year":"2008","journal-title":"Cancer Immunology Immunotherapy"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/ERC-17-0427","article-title":"Inflammation and and PD-L1 expression in pulmonary neuroendocrine tumors","volume":"25","year":"2018","journal-title":"Endocrine-Related Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2017.01830","article-title":"Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?","volume":"8","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1530\/ERC-12-0024","article-title":"tumor disease an evolving - Related https org","volume":"19","author":"Neuroendocrine","year":"2012","journal-title":"landscape Endocrine Cancer"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"e3004","DOI":"10.1038\/cddis.2017.401","article-title":"Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading","volume":"8","year":"2017","journal-title":"Cell Death and Disease"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7150\/jca.13711","article-title":"The impact of PD-L1 expression in patients with metastatic GEP-NETs","volume":"7","year":"2016","journal-title":"Journal of Cancer"},{"key":"ref141","first-page":"13","article-title":"Nomenclature and classification of neuroendocrine neoplasms of the digestive system","year":"2010","journal-title":"World Health Organization Classification of Tumours of the Digestive System"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"14922","DOI":"10.18632\/oncotarget.24464","article-title":"PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours","volume":"9","year":"2018","journal-title":"Oncotarget"},{"key":"ref81","article-title":"A quantitative comparison of antibodies to programmed cell death 1 ligand 1","year":"2016","journal-title":"JAMA Oncology"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","year":"2016","journal-title":"JAMA Oncology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/02841860802438495","article-title":"Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue","volume":"48","year":"2009","journal-title":"Acta Oncologica"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1200\/JCO.2008.17.6149","article-title":"Ectopic lymph nodes within human solid tumors","volume":"26","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.humpath.2017.10.003","article-title":"Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1\/PD-L1 therapy","volume":"70","year":"2017","journal-title":"Human Pathology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","article-title":"Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling","volume":"179","year":"2011","journal-title":"American Journal of Pathology"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","year":"2015","journal-title":"Cancer Research"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/ERC-16-0370","article-title":"WOMEN IN CANCER THEMATIC systemic therapies in neuroendocrine tumors and novel approaches toward personalized - Related https org","volume":"23","author":"PavelMESersC","year":"2016","journal-title":"REVIEW medicine Endocrine Cancer"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/26\/1\/ERC-18-0189.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/26\/1\/ERC-18-0189.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:54:58Z","timestamp":1784555698000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/26\/1\/119-130\/25398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":20,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/erc-18-0189","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}